Resolving Histologic Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programs.
Fiche publication
Date publication
avril 2023
Journal
Journal of Crohn's & colitis
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Magro F, Pai RK, Kobayashi T, Jairath V, Rieder F, Redondo I, Lissoos T, Morris N, Shan M, Park M, Peyrin-Biroulet L
Lien Pubmed
Résumé
To evaluate the effect of mirikizumab, a p19-targeted anti-interleukin-23, on histologic and/or endoscopic outcomes in moderately-to-severely active ulcerative colitis [UC].
Mots clés
Histologic remission, mirikizumab, ulcerative colitis
Référence
J Crohns Colitis. 2023 04 14;: